Taking Wing With Biotech Angel Investors
This article was originally published in Start Up
They’re not just for seed rounds anymore: in the life sciences, rich individuals are supplying more early stage capital than ever, occasionally well past the Series A stage, and some are banding together into groups that look increasingly like traditional venture capital. How far will this phenomenon fly?
Register for our free email digests: